Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 4:43 PM
Ignite Modification Date:
2025-12-24 @ 4:43 PM
NCT ID:
NCT07011966
Eligibility Criteria:
Inclusion Criteria:
* ≥ 18 years old
* Complaint of insomnia when presenting at clinic
* Diagnosis of moderate to severe insomnia through the Insomnia Severity Index (ISI) with a score ≥ 15
* Meet diagnostic criteria of Insomnia Disorder (per American Academy of Sleep Medicine)
* Naïve to treatment for sleep-disordered breathing (SDB), including CPAP, APAP, ASV; mandibular repositioning devices (MRDs), and any other nasal or oral therapy with a primary indication of treating SDB
* Owns a smartphone and is able to install an application for HSAT data syncing.
* Able to fully understand study information in English and sign informed consent
Exclusion Criteria:
* Primary complaint of sleep-disordered breathing or issues with apneas during sleep or excessive daytime sleepiness
* Pregnant or planning to be pregnant
* Any prior diagnosis of severe respiratory disorder or severe sleep disorder such as restless leg syndrome (RLS), idiopathic hypersomnia, or narcolepsy
* High risk for moderate to severe OSA based on STOP-BANG score.
* BMI \> 40 kg/m2
* Anticipated changes to start or stop sedative or psychotropic medications during the course of the trial.
* Medical history of congestive heart failure (CHF) or other potentially unstable cardiac disease as well as chronic lung diseases or other debilitating medical conditions that manifest as more prominent in the patient's health compared to their sleep complaints.
* Daily use of opiate medications
* Known contraindications to PAP therapy as listed in the indication for use (i.e. heart failure (NYHA 2-4) with reduced left ventricular ejection fraction (LVEF ≤45%) and moderate to severe predominant central sleep apnea).
* Inability to pre-emptively comply with study procedures
* Patients who wish to continue using sleeping pills/hypnotics during the study
* Patients with conditions affecting the rotation of the condyle in the temporo-mandibular joint.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT07011966
Study Brief:
Protocol Section:
NCT07011966